These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 30440160)

  • 21. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW; Bressler SB
    Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.
    Shiba T; Takahashi M; Yoshida I; Taniguchi H; Matsumoto T; Hori Y
    Ophthalmologica; 2016; 235(4):225-32. PubMed ID: 27082736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of genetic mutations on clinical presentation of subretinal neovascularization. Report 2: The impact of HTRA and VEGF genes polymorphism].
    Budzinskaia MV; Pogoda TV; Strelkova ID; Chikun EA; Shchegoleva IV; Kazarian ÉÉ; Galoian NS
    Vestn Oftalmol; 2011; 127(4):9-16. PubMed ID: 21882634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss.
    Francis PJ; Hamon SC; Ott J; Weleber RG; Klein ML
    J Med Genet; 2009 May; 46(5):300-7. PubMed ID: 19015224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.
    Zhou YL; Chen CL; Wang YX; Tong Y; Fang XL; Li L; Wang ZY
    BMC Ophthalmol; 2017 Jun; 17(1):97. PubMed ID: 28637435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
    Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P
    Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
    Nielsen JS; Fick TA; Saggau DD; Barnes CH
    Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane.
    Kimura S; Morizane Y; Toshima S; Hosogi M; Kumase F; Hosokawa M; Shiode Y; Fujiwara A; Shiraga F
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1731-6. PubMed ID: 26951250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.
    Wu M; Xiong H; Xu Y; Xiong X; Zou H; Zheng M; Wang X; Zhou X
    Br J Ophthalmol; 2017 Jul; 101(7):976-984. PubMed ID: 28400373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
    Lee SJ; Koh HJ
    Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration.
    Krebs I; Glittenberg C; Ansari-Shahrezaei S; Hagen S; Steiner I; Binder S
    Br J Ophthalmol; 2013 Nov; 97(11):1443-6. PubMed ID: 23966368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.
    Finger PT; Chin KJ; Semenova EA
    Eur J Ophthalmol; 2016; 26(1):60-6. PubMed ID: 26391167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The pharmacogenomics of CFH Y402H and wet age-related macular degeneration].
    Chen LL; Chen YY
    Zhonghua Yan Ke Za Zhi; 2017 Feb; 53(2):144-147. PubMed ID: 28260367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.